All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Definition and clinical significance of the MGUS-like phenotype in patients with monoclonal gammopathies

May 17, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in monoclonal gammopathies.

The Multiple Myeloma Hub was pleased to speak with steering committee member, Bruno Paiva, University of Navarra, Pamplona, ES. We asked, What is the definition and clinical significance of the monoclonal gammopathy of undetermined significance (MGUS)–like phenotype in patients with monoclonal gammopathies?

Definition and clinical significance of the MGUS-like phenotype in monoclonal gammopathies

In this presentation, Paiva summarizes a recent publication1 and discusses the current lack of standardized methods to identify the subgroup of patients with multiple myeloma and light-chain (AL) amyloidosis who have MGUS-like phenotype. He goes on to outline the flow cytometry-based tool that was developed to address this issue and provides the key data it produced with a focus on progression-free and overall survival outcomes. Paiva concludes with the clinical applications of this tool and discusses how these data can help subdivide groups of patients to inform a more individualized treatment approach.

Downloadable presentation

To download this resource, click below.

Download here

  1. Burgos L, Tamariz-Amador LE, Puig N, et al. Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies. J Clin Oncol. 2023. Online ahead of print. DOI: 1200/JCO.22.01916


Subscribe to get the best content related to multiple myeloma delivered to your inbox